We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 2.94% | 17.50 | 17.00 | 18.00 | 17.50 | 17.50 | 17.50 | 7,648 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -6.5M | -0.0683 | -2.56 | 16.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/1/2024 13:08 | Just for total clarity these are the major shareholder reporting rules: "A person must notify the issuer of the percentage of its voting rights he holds as shareholder or holds or is deemed to hold through his direct or indirect holding of financial instruments falling within DTR 5.3.1R (1) (or a combination of such holdings) if the percentage of those voting rights: (1) reaches, exceeds or falls below 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% and each 1% threshold thereafter up to 100% (or in the case of a non-UK issuer on the basis of thresholds at 5%, 10%, 15%, 20%, 25%, 30%, 50% and 75%) as a result of an acquisition or disposal of shares or financial instruments falling within DTR 5.3.1 R; or (2) reaches, exceeds or falls below an applicable threshold in (1) as a result of events changing the breakdown of voting rights and on the basis of information disclosed by the issuer in accordance with DTR 5.6.1 Rand DTR 5.6.1A R; and in the case of an issuer which is not incorporated in the United Kingdom a notification under (2) must be made on the basis of equivalent events and disclosed information." That said, reporting standards on AIM are quite lax and it is more often the case that notification of a disposal or acquisition of shares (voting rights) will not be disclosed until after the transaction is completely finished and that's possibly the case with our seller, particularly so if my hunch is correct. As previously mentioned, the share price has shown good strength during this period and one does wonder where we would be without the continual drip feed of stock into the market. The boss is presumably back in the office on Monday, following his trip to the States, and perhaps he has some data from NIAID in his briefcase or waiting on his desk :) | captain james t kirk | |
13/1/2024 11:29 | marvelman I agree wholeheartedly. | parsons4 | |
12/1/2024 17:22 | Yes and that's the trouble. 3% is circa 2.9 million shares that we would have to contend with (If it were so). Even those that cause a 1% change above 3% that they held would be required to notify which is still almost a million shares. We just have to be patient. The seller or sellers are currently being well managed by the MM's. We have had a good week and that much closer to our anticipated RNS | marvelman | |
12/1/2024 16:37 | If any entitys sharehoding falls below 3% is no longer considered a major shareholder as far as I know. | 2cmb | |
12/1/2024 12:49 | Looking good here. Might the announcement that we await spark a Global to commit? | carlisle44 | |
12/1/2024 12:41 | I don't know how you found this snippet Captain but many thanks | marvelman | |
12/1/2024 12:35 | Looks as if it's going to push thru 80p soon | xcap1 | |
12/1/2024 12:14 | I disagree Eg he has 6% as each 1% is crossed eg to 5% a tr1 form should issued via rns | xcap1 | |
12/1/2024 11:54 | To access the accounts search here: From memory note 9 is the relevant one. | captain james t kirk | |
12/1/2024 11:41 | That's very interesting Captain. You certainly do your research and it makes a lot of sense. What entity do they show under as I cannot see the name under on the share register of major holders | marvelman | |
12/1/2024 11:11 | As I mentioned some time ago, it's obviously an orderly market sell, which I believe to have started in the summer. My best guess is that it is the Wade Furniture Group disposing of their 1.25 million stake, against last reported losses of £1.5 million in the business. If correct, there should not be many left to sell and then the brakes can be released. | captain james t kirk | |
12/1/2024 11:04 | John Henry the 10k seller could have around 2.5 million shares bould when it was low. No TR1 is needed at less than 3 percent. So selling 10K or 5 K a day will take a long time. Those amounts do not effect the price and they can make a nice profit as the share rises and top up when it falls a bit. | controlledmadness | |
12/1/2024 10:56 | Ffs I opened the link thinking it's a broker note or interview lol!!!!! I suppose it could be | xcap1 | |
12/1/2024 10:53 | LOL :-)CJK let's hope so. :-):-) | 2cmb | |
12/1/2024 10:47 | Only way is up! Good news next week? GLA | mam fach | |
12/1/2024 09:47 | Which way will we swing today ? | arab3 | |
12/1/2024 09:44 | Soon absorbed, not much stock about !! | parsons4 | |
12/1/2024 08:23 | Yesterday's gap up filled 10k seller back | john henry | |
11/1/2024 17:34 | DP previously announced peak sales of over 2 billion dollars for XF nasal. So not sure where article got 1 billion from. Maybe it's dermal they r getting confused about and its market peak sales are 1 billion. | supracat | |
11/1/2024 16:40 | slowly clearing all the weak holders | john henry | |
11/1/2024 16:30 | The ubiquitous 1 trade. Holders want good news non holders bad news? Got to be in it to win it. | mam fach | |
11/1/2024 06:33 | Strange one that article was released on the 8th but it's got zero visibility on the website unless you search for Destiny pharma. It's not been seen by many yet. | mikeh30 | |
11/1/2024 00:12 | Potential sales of over $1billion | xcap1 | |
10/1/2024 23:57 | I like this bit lolIn doing the sums, our abacus rattlers have come up with a per share valuation range of 120p-285p a share, or a market cap of £113 million to almost £270 million. | xcap1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions